Atlas Trials

HER2-positive Gastric Cancer

43 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch HER2-positive Gastric Cancer

RecordFirmDate
RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer (NCT05313906)Henan Cancer Hospital2022-05-07
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer (NCT05311189)Shanghai Zhongshan Hospital2022-04-15
Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial (NCT05270889)Yonsei University2022-04-01
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers (NCT05091528)Silverback Therapeutics2022-02-08
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System (NCT05165602)Peking University2022-01-01
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma (NCT05190445)Pieris Pharmaceuticals, Inc.2021-11-01
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer (NCT05070598)Shengjing Hospital2021-09-07
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117)QuantumLeap Healthcare Collaborative2021-07-28
TAC T-cells for the Treatment of HER2-positive Solid Tumors (NCT04727151)Triumvira Immunologics, Inc.2021-04-19
Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients (NCT04920747)Centre Hospitalier Universitaire de Besancon2021-04-01
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967)NKGen Biotech, Inc.2021-03-01
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929)Carisma Therapeutics Inc2021-02-02
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (NCT04650451)Bellicum Pharmaceuticals2020-12-07
ctDNA Screening in Advanced HER2 Positive Gastric Cancer (NCT04520295)Ruijin Hospital2020-05-19
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (NCT04082364)MacroGenics2019-09-30
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (NCT03409848)AIO-Studien-gGmbH2018-03-01
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (NCT03319459)Fate Therapeutics2018-01-18
PRS-343 in HER2-Positive Solid Tumors (NCT03330561)Pieris Pharmaceuticals, Inc.2017-09-13
Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer (NCT02378389)Jiangsu HengRui Medicine Co., Ltd.2014-09-01

Track HER2-positive Gastric Cancer automatically

Every clearance here is in the API, with alerts when new ones post.